Introduction {#sec1}
============

Advances in molecular biology and biochemical engineering have led to the development of molecular target-based therapies against cancers, which are expected to be less toxic than chemotherapeutic agents. Antisense oligonucleotides (ASOs), single-stranded, 12- to 25-residue-length nucleic acids, bind to the complementary mRNA sequences coding for target molecules and inhibit gene translation via degradation of the mRNA by endogenous RNase H activity.[@bib1], [@bib2], [@bib3] However, unmodified ASOs, with phosphodiester-linked structures, have limited effectiveness in vivo because they are vulnerable to endogenous nucleases. To address this problem, chemically modified ASOs incorporated by locked nucleic acids (LNAs) or amido-bridged nucleic acids (AmNAs) with phosphorothioate-linked structures have been developed to achieve higher affinity and nuclease resistance with lower toxicity.[@bib4], [@bib5], [@bib6]

To design ASO reagents useful for treating cancer patients, it is important to select target molecules that are upregulated in cancerous tissue regions and are related to tumor survival and progression. Y-box binding protein-1 (YB-1), originally identified as a member of the cold-shock protein superfamily,[@bib7], [@bib8] is overexpressed not only in cancer cells,[@bib9], [@bib10], [@bib11], [@bib12] but also in vascular endothelia in tumor tissues.[@bib13] YB-1 plays an important role in proliferation, invasion, multi-drug resistance, and malignant transformation in a variety of cancers.[@bib14], [@bib15], [@bib16] YB-1 may also be involved in signaling by vascular endothelial growth factor (VEGF), a critical factor for angiogenesis.[@bib17], [@bib18], [@bib19] However, the biological significance of YB-1 in angiogenesis in a tumor microenvironment has not been well elucidated,[@bib20], [@bib21] because intracellular delivery of the RNAi and protein reagents has not met full success in vivo, although in vitro and ex vivo transfection of small interfering RNAs (siRNAs) or dominant negative YB-1 mutants inhibits YB-1 activation and decreases viabilities of cancer cells[@bib22], [@bib23] and vascular endothelial cells.[@bib24] We hypothesize LNA- and/or AmNA-based YB-1-targeting ASOs (designated as YB-1 ASO^L^ and YB-1 ASO^A^, respectively) may enable evaluation of the influence of YB-1 on angiogenesis in the tumor microenvironment, including cancer cells and stromal vasculatures.

In this study, we established YB-1 ASO^A^ as an efficient YB-1 knockdown system in vivo and demonstrated that YB-1 ASO^A^ exhibited antiangiogenic effects on proliferating vascular endothelial cells in the tumor microenvironment, mediated by the blockade of VEGF receptor (VEGFR) and Tie receptor signaling via Bcl-xL suppression. These results not only demonstrate the feasibility of YB-1 ASO^A^-based tumor dormancy therapy for intractable cancers in vivo but also provide proof of principle for the significance of YB-1 signaling in tumor angiogenesis.

Results {#sec2}
=======

Establishment of an ASO-Based YB-1 Knockdown System {#sec2.1}
---------------------------------------------------

We generated a 15-mer ASO containing nucleic acids (ASO^NA^) and chemically modified ASOs flanked by LNAs or AmNAs, with phosphorothioate-linked structures, targeting both mouse and human *YBX1* mRNAs (YB-1 ASO^NA^, YB-1 ASO^L^, and YB-1 ASO^A^, respectively) ([Figure 1](#fig1){ref-type="fig"}A; [Figure S1](#mmc1){ref-type="supplementary-material"}). The sequences of ASOs were 5′-TmCT cct gca ccmC TGg-3′ for YB-1 ASOs and 5′-mCAT ttc gaa gtA mCT c-3′ for control ASO (uppercase, LNA or AmNA; lowercase, DNA; mC, 5-methylated cytosine). YB-1 ASO^L^ and YB-1 ASO^A^ showed superior thermal stabilities (T~m~ values), as an index of binding affinity to complementary RNA strands, compared to ASO^NA^ ([Figure 1](#fig1){ref-type="fig"}B). Correspondingly, knockdown efficiencies of YB-1 ASO^A^ and YB-1 ASO were greater than that of YB-1 ASO^NA^, at both mRNA and protein levels, in vascular endothelial and pancreatic cancer MIA PaCa-2 cells ([Figures 1](#fig1){ref-type="fig"}C and 1D). YB-1 ASO^A^ exhibited slightly higher knockdown efficiency than YB-1 ASO^L^, but the difference was not significant ([Figures 1](#fig1){ref-type="fig"}C and 1D). To identify which ASO was most useful for in vivo application, we evaluated their safety potentials when systemically administered. In mice receiving YB-1 ASO^L^, but not YB-1 ASO^A^, there was elevated serum alanine aminotransferase (ALT) and total bilirubin (T. Bil), indicators of liver damage ([Figure 1](#fig1){ref-type="fig"}E), although renal function was not different between YB-1 ASO^L^ and YB-1 ASO^A^ (BUN, 24 ± 3 versus 22 ± 6 mg/dL; creatinine, 0.10 ± 0.02 versus 0.09 ± 0.02 mg/dL; n = 4). Therefore, we decided to use YB-1 ASO^A^ for subsequent experiments to investigate in vivo efficacy and potential mechanism of action.Figure 1Construction of YB-1 ASOs and Their Effects on YB-1 mRNA and Protein Expression In Vitro(A) Schematic structures of several types of YB-1 ASOs. (B) T~m~ values of YB-1 ASO duplexes with DNA and RNA target strands. (C) qRT-PCR of human *YBX1* mRNA in HUVECs, HPAECs, and MIA PaCa-2 cells transfected with YB-1 ASOs or control ASO (normalized to *B2M*). n = 3. (D) Immunoblots for YB-1 protein in HUVECs, HPAECs, and MIA PaCa-2 cells transfected with YB-1 ASOs or control ASO (5 nM). β-actin is the loading control. (E) Effects of i.v. administered YB-1 ASO^A^, YB-1 ASO^L^, or control ASO (once per week for 3 weeks at 10 mg/kg body weight) on liver function, evaluated by alanine aminotransferase (ALT) and T. Bil values. \*p \< 0.01; n = 4 per group. Data are means ± SD.

Antitumor Efficacy of i.v. Administered YB-1 ASO^A^ in Mice Harboring Subcutaneous Tumor Xenografts {#sec2.2}
---------------------------------------------------------------------------------------------------

YB-1 ASO^A^, administered intravenously (i.v.), inhibited tumor growth by more than 50%, compared with control injected mice, on day 21 in the Suit2-GR and HCT116 xenograft models (\*p \< 0.05, \*\*p \< 0.01) ([Figure 2](#fig2){ref-type="fig"}A). The xenograft tumors consisted of mouse stromal cells and implanted human cancer cells; thus, we evaluated knockdown efficiency of mouse and human *YBX1* in tumor tissues using qRT-PCR with different primers to detect mouse and human *YBX1*. Expression of mouse *YBX1* mRNA was significantly inhibited in liver, kidney, and tumor tissues in mice receiving i.v. administered YB-1 ASO^A^, compared with controls (\*\*p \< 0.001) ([Figure 2](#fig2){ref-type="fig"}B). In contrast, human *YBX1* expression in tumor tissues was not inhibited.Figure 2Antitumor Efficacy of i.v. Administered YB-1 ASO^A^ in Mice Harboring Subcutaneous Tumor Xenografts(A) Antitumor efficacy of i.v. administered YB-1 ASO^A^ (once per week for 3 weeks at 10 mg/kg body weight) in mice bearing HCT116 or Suit2-GR xenografts. \*p \< 0.05, \*\*p \< 0.01; n = 7 per group. Black arrows represent administered time points of ASOs. (B) qRT-PCR of mouse *YBX1* mRNA in liver, kidney, or tumor and human *YBX1* mRNA in tumor tissues from mice harboring HCT116 and Suit2-GR xenografts and receiving YB-1 ASO^A^ treatments (once per week for 3 weeks at 10 mg/kg body weight). \*\*p \< 0.001; n = 7 per group. Values are normalized to those for mouse or human 18S rRNAs. Data are means ± SD.

Antitumor Efficacy of i.v. Administered YB-1 ASO^A^ Is Mediated by Antiangiogenic Effects {#sec2.3}
-----------------------------------------------------------------------------------------

We hypothesized that the antitumor efficacy of YB-1 ASO^A^ was mediated by angiogenesis inhibition rather than by a direct effect to cancer cells in the subcutaneous tumors, and we examined microvascular density in the tumor tissues by immunostaining for the mouse angiogenic marker CD31 ([Figure 3](#fig3){ref-type="fig"}A). In mice given i.v. administered YB-1 ASO^A^, the numbers of angiogenic vascular endothelial cells in HCT116 and Suit2-GR tumors decreased to 48% and 57%, respectively, compared with those in controls (\*p \< 0.05, \*\*p \< 0.01) ([Figure 3](#fig3){ref-type="fig"}B), whereas the level of CD31 staining was not high in the liver or kidneys and was not affected by YB-1 ASO^A^ i.v. administration ([Figure S3](#mmc1){ref-type="supplementary-material"}). Next, we performed double staining for CD31 and YB-1 to analyze YB-1 expression in angiogenic endothelial cells in subcutaneous Suit2-GR tumors. YB-1 expression was greatly reduced in CD31-positive angiogenic endothelial cells in tumor tissues after i.v. administration of YB-1 ASO^A^, but not in most cancer cells ([Figure 3](#fig3){ref-type="fig"}C). This was consistent with the qRT-PCR results for mouse and human *YBX1* mRNA expression ([Figure 2](#fig2){ref-type="fig"}B).Figure 3i.v. Administered YB-1 ASO^A^ Suppresses Tumor Growth In Vivo through Antiangiogenic Effects on Host Vascular Cells(A) Representative immunostaining images showing CD31 in HCT116 and Suit2-GR tumors after YB-1 ASO^A^ treatment (once per week for 3 weeks at 10 mg/kg body weight). Scale bar, 200 μm. (B) Quantification of microvascular density, assessed by CD31 staining per field, in HCT116 and Suit2-GR tumor tissues. \*p \< 0.05, \*\*p \< 0.01; n = 6. Data are means ± SD. (C) Representative immunostaining images for YB-1 and CD31 in Suit2-GR tumor tissues in mice treated with YB-1 ASO^A^ or control ASO (once per week for 3 weeks at 10 mg/kg body weight). Scale bar, 20 μm. (D) Representative immunostaining images showing cleaved caspase-3 (c-caspase-3) and mouse CD31 in Suit2-GR tumor tissues from mice receiving i.v. YB-1 ASO^A^ treatment (once per week for 3 weeks at 10 mg/kg body weight). Yellow signal (arrowhead) in merged images represents apoptosis (c-caspase-3) in CD31-positive angiogenic endothelial cells. Scale bar, 50 μm. The fluorescent signal images (C and D) were obtained using immunofluorescence laser confocal microscopy. (E) Immunostaining of c-caspase-3 in Suit2-GR tumors from mice treated with i.v. administered YB-1 ASO^A^ (once per week for 3 weeks at 10 mg/kg body weight). YB-1 ASO^A^-treated, but not control, tumors had apoptotic cells. Scale bar, 200 μm.

To further examine the cause of decreased microvascular density in YB-1 ASO^A^-treated tumors, we evaluated apoptosis induction in vascular endothelial cells in HCT116 and Suit2-GR tumors treated with YB-1 ASO^A^. Apoptosis in angiogenic vascular cells was assessed by double staining for CD31 and cleaved caspase-3, a member of the cysteine-aspartic acid protease (caspases) family. Those cells that were intensely stained for cleaved caspase-3 were co-localized with angiogenic endothelial cells, positive for mouse CD31, in tumors treated with YB-1 ASO^A^ ([Figure 3](#fig3){ref-type="fig"}D, arrowheads). In contrast, only a few cells positive for cleaved caspase-3 were detected in the control tumors ([Figure 3](#fig3){ref-type="fig"}E). These results suggest that i.v. administered YB-1 ASO^A^ efficiently distributed to tumor vessels and induced apoptosis in angiogenic vascular endothelial cells, resulting in the inhibition of tumor growth.

YB-1 ASO^A^ Inhibits Proliferation and Tube Formation of Vascular Endothelial Cells {#sec2.4}
-----------------------------------------------------------------------------------

To explore the mechanism of YB-1 ASO^A^ on inhibition of tumor angiogenesis, phenotypic changes by YB-1 knockdown were examined in human umbilical vein endothelial cells (HUVECs) and human pulmonary artery endothelial cells (HPAECs). Transfection with YB-1 ASO^A^ significantly inhibited proliferation of HUVECs and HPAECs (\*p \< 0.05, \*\*p \< 0.01) ([Figure 4](#fig4){ref-type="fig"}A) and decreased the proportion of cells in G2/M phase to approximately 60% and 50% of the controls in YB-1 ASO^A^-treated HUVECs and HPAECs, respectively. Conversely, the proportion at sub-G1 phase, a fraction of apoptotic cells, was increased approximately 20-fold in HUVECs and HPAECs treated with YB-1 ASO^A^ compared with controls (\*p \< 0.05, \*\*p \< 0.01) ([Figure 4](#fig4){ref-type="fig"}B).Figure 4Involvement of YB-1 in Proliferation, Apoptosis, and Tube Formation in Vascular Endothelial CellsHUVECs and HPAECs were transfected with YB-1 ASO^A^ or control ASO^A^ (5 nM) and subjected to the following analyses. (A) Cell proliferation analysis with the WST-8 assay. \*p \< 0.05, \*\*p \< 0.01; n = 3. (B) Cell-cycle distribution, analyzed in HUVEC and HPAEC by staining the DNA content with propidium iodide. The distribution was measured by flow cytometry. \*p \< 0.05, \*\*p \< 0.01; n = 3. (C) Western blot analysis shows robustly increased c-caspase-3 (apoptosis) and decreased YB-1 levels in YB-1 ASO^A^-transfected cells. β-actin is the loading control. (D) Cytochrome *c* release from the IMS was detected in HUVECs and HPAECs transfected with YB-1 ASO^A^ in the presence of a pan-caspase inhibitor, Z-VAD-FMK, under immunofluorescence laser confocal microscopy. Data were obtained from 50 cells in each of three independent experiments. Quantitated levels of released cytochrome *c* were higher in cells with YB-1 ASO^A^ transfection than in controls. \*p \< 0.001. (E) Representative images showing tube formation in HUVEC and HPAEC cultures transfected with YB-1 ASO^A^ or control. Scale bar, 200 μm. (F) Quantitation of total tube length in 10 randomly chosen images using ImageJ software. \*p \< 0.001. Data are means ± SD.

Western blot analysis also showed robust cleavage of caspase-3, indicating induction of apoptosis, in cells with YB-1 knockdown, but not in controls ([Figure 4](#fig4){ref-type="fig"}C). We further evaluated apoptosis by the release of a pro-apoptotic protein, cytochrome *c*, from the mitochondrial intermembrane space (IMS), an upstream event of caspase activation.[@bib25] Cytochrome *c* release from mitochondrial marker protein TOMM20 ([Figure S4](#mmc1){ref-type="supplementary-material"}) was observed in 41.6% of HUVECs and 38% of HPAECs with YB-1 knockdown, whereas no cytochrome *c* release was observed in controls (\*\*p \< 0.001) ([Figure 4](#fig4){ref-type="fig"}D).

We next examined the effects of YB-1 ASO^A^ on angiogenesis by in vitro tube formation assay mimicking capillary-like structure formation of angiogenic endothelial cells in the critical process of angiogenesis in vivo.[@bib19] Tube formation was significantly inhibited to approximately 20% and 10% of control levels in HUVECs and HPAECs, respectively, transfected with YB-1 ASO^A^ (\*p \< 0.01) ([Figures 4](#fig4){ref-type="fig"}E and 4F).

YB-1 ASO^A^-Mediated Bcl-xL Reduction Induces Apoptosis and Inhibition of Tube Formation in Vascular Endothelial Cells {#sec2.5}
----------------------------------------------------------------------------------------------------------------------

To explore factors downstream of YB-1 signaling, we examined gene expression profiles in YB-1 ASO^A^-transfected HUVEC and HPAEC using cDNA microarray analysis. The microarray analysis showed that expression of Bcl-xL, a member of the antiapoptotic Bcl-2 family of proteins, was significantly decreased in YB-1 ASO^A^-transfected cells (\*p \< 0.001) ([Figure 5](#fig5){ref-type="fig"}A). qRT-PCR and western blot confirmed repression of Bcl-xL expression at both mRNA and protein levels in HUVECs and HPAECs with YB-1 knockdown ([Figures 5](#fig5){ref-type="fig"}B and 5C). Consistently, transfection of Bcl-xL siRNA induced apoptosis (cleaved caspase-3 \[c-caspase-3\]) in HUVEC and HPAEC but did not change YB-1 expression ([Figure 5](#fig5){ref-type="fig"}D). Bcl-xL knockdown inhibited cell proliferation (\*p \< 0.05, \*\*p \< 0.01) ([Figure 5](#fig5){ref-type="fig"}E) and tube formation ([Figure 5](#fig5){ref-type="fig"}F) in a manner similar to YB-1 ASO^A^ transfection in HUVECs and HPAECs. That is, formation of capillary-like structures was impaired similarly with both YB-1 and Bcl-xL knockdown, indicating that Bcl-xL acted downstream of the YB-1 signal. We assessed whether Bcl-xL overexpression reverses inhibition of vascular endothelial cell tube formation by YB-1 ASO^A^. Transduction of Bcl-xL by adeno-associated virus 2 particles partially rescued the YB-1 knockdown-mediated impairment of tube formation in HUVECs and HPAECs treated with YB-1 ASO^A^, suggesting that other factors downstream of YB-1, in addition to Bcl-xL, may be involved in tube formation in vascular endothelial cells ([Figure S5](#mmc1){ref-type="supplementary-material"}; [Supplemental Materials and Methods](#mmc1){ref-type="supplementary-material"}).Figure 5YB-1 ASO^A^-Induced Apoptosis and Inhibition of Tube Formation Are Mediated by Bcl-xL Reduction in Vascular Endothelial Cells(A) Heatmap analysis of cDNA microarray data showing highly downregulated *Bcl-xL* expression, among Bcl-2 family genes, in HUVECs and HPAECs transfected with YB-1 ASO^A^ (5 nM). (B) Downregulation of *Bcl-xL* expression was confirmed by qRT-PCR analysis (normalized to values for *18S*). \*p \< 0.01; n = 3. Data are means ± SD. (C) Immunoblots for Bcl-xL and YB-1 in HUVECs and HPAECs transfected with YB-1 ASO^A^ or control ASO (5 nM). β-actin is the loading control. (D) Western blot analysis shows an increase in c-caspase-3 but no change in YB-1 protein levels in HUVECs and HPAECs transfected with Bcl-xL siRNA (5 nM). (E) Cell proliferation, assessed by WST-8 assay, was decreased in HUVECs and HPAECs by transfection with Bcl-xL siRNA. \*p \< 0.05, \*\*p \< 0.01. (F) Capillary-like tube formation was inhibited by transfection with Bcl-xL siRNA or YB-1 ASO^A^ in HUVECs and HPAECs. Scale bar, 200 μm.

VEGFR2 and Tie Receptor Expression Is Inhibited by YB-1/Bcl-xL Knockdown in Human Vascular Endothelial Cells {#sec2.6}
------------------------------------------------------------------------------------------------------------

We hypothesized that YB-1/Bcl-xL knockdown-mediated apoptosis may be related to the VEGF and VEGFR or angiopoietin/Tie pathway, because VEGF-VEGFR and angiopoietin-Tie receptor systems are the two major signaling pathways critical for a variety of vascular endothelial cell functions.[@bib26], [@bib27], [@bib28] Proliferation of HUVECs and HPAECs was moderately enhanced under the presence of a high concentration of VEGF (5 times higher than the manufacturer's endothelial medium) or angiopoietin-1 (400 ng/mL) in a culture medium, but YB-1 ASO^A^-mediated inhibition of cell proliferation was not affected under the same culture conditions ([Figure 6](#fig6){ref-type="fig"}A). YB-1 protein expression or YB-1 knockdown efficiency was not changed by addition of VEGF or angiopoietin-1 ([Figures S6](#mmc1){ref-type="supplementary-material"}A and S6B) or withdrawal of VEGF ([Figures S6](#mmc1){ref-type="supplementary-material"}C and S6D) in the culture media in HUVECs and HPAECs. Expression of VEGFR2, Tie1, and Tie2, but not VEGFR1, was significantly reduced in YB-1 ASO^A^-transfected HUVECs and HPAECs ([Figure 6](#fig6){ref-type="fig"}A). Bcl-xL knockdown also decreased levels of these receptors, although it did not change YB-1 expression ([Figure 6](#fig6){ref-type="fig"}B). The pan-caspase inhibitor z-VAD-fmk did not affect the decreased VEGFR2 expression caused by YB-1 knockdown, whereas it inhibited cleavage of its target caspase-3 ([Figure S7](#mmc1){ref-type="supplementary-material"}). These results suggest that YB-1 regulates expression of VEGFR2 and Tie receptors via an upstream Bcl-xL-mediated pathway, irrespective of caspase activation.Figure 6Knockdown of YB-1/Bcl-xL Downregulates VEGFR2 and Tie-1/-2 Expression in Angiogenic Endothelial Cells in Tumor Microenvironments(A and B) Western blot analysis showing inhibition of VEGFR2 and Tie-1/-2 expression in HUVECs or HPAECs transfected with YB-1 ASO^A^ (5 nM) (A) or Bcl-xL siRNA (20 nM) (B). β-actin is the loading control. (C) Antitumor efficacy of YB-1 ASO^A^ treatment (once per week for 4 weeks at 10 mg/kg body weight) was superior to that of bevacizumab (twice per week for 4 weeks at 10 mg/kg body weight) in mice bearing Suit2-GR xenografts. \*p \< 0.05; n = 9. Data are means ± SD. Red and black arrows represent administered time points of bevacizumab and ASOs, respectively. (D) Immunohistochemistry for VEGFR2, Tie2, and CD31 in the Suit2-GR tumors using laser confocal microscopy. The images show inhibition of Tie2 signals in CD31-positive angiogenic endothelial cells in tumor tissues treated with i.v. administered YB-1 ASO^A^ (once per week for 4 weeks at 10 mg/kg body weight), but not in the controls. Scale bar, 20 μm.

VEGFR2 and Tie2 Expression Is Inhibited in Suit2-GR Subcutaneous Tumors Treated with i.v. Administered YB-1 ASO^A^ {#sec2.7}
------------------------------------------------------------------------------------------------------------------

We then compared YB-1 ASO^A^ and an anti-VEGF antibody (bevacizumab) for antitumor efficacy in vivo. Tumor growth was significantly inhibited by YB-1 ASO^A^ treatment (\*p \< 0.05 on days 14--28 versus the control ASO group). In contrast, the antitumor efficacy of bevacizumab was inefficient, with no significant reduction in tumor volumes compared with a control antibody-treated group ([Figure 6](#fig6){ref-type="fig"}C).To examined why bevacizumab-insensitive Suit2-GR tumors were susceptible to YB-1 ASO^A^ treatment, we carried out the immunohistochemistry of VEGFR2 and Tie2 receptors in Suit2-GR subcutaneous tumor tissues in mice receiving i.v. administered YB-1 ASO^A^, because YB-1 knockdown inhibited the expression of Tie2 receptor, another major mediator of angiogenesis besides VEGF/VEGFR2, in HUVECs and HPAECs. Tie2 expression was greatly decreased in subcutaneous Suit2-GR tumor tissues treated with YB-1 ASO^A^ compared with those in controls ([Figure 6](#fig6){ref-type="fig"}D).

Antitumor Efficacy of i.p. Administered YB-1 ASO^A^ in Mice Harboring Peritoneally Disseminated Tumors {#sec2.8}
------------------------------------------------------------------------------------------------------

YB-1 ASO^A^, when administered intraperitoneally (i.p.), significantly inhibited not only mouse but also human *YBX1* mRNA expression in peritoneally disseminated RMG-1 tumors (p \< 0.05; n = 5) ([Figure 7](#fig7){ref-type="fig"}A). Accordingly, i.p. administered YB-1 ASO^A^ significantly suppressed the growth of disseminated RMG-1 tumors compared with the controls (p \< 0.05 on days 21) ([Figure 7](#fig7){ref-type="fig"}B). Correspondingly, immunohistochemical analysis showed decreased YB-1 and increased cleaved caspase-3 expression not only in mouse CD31-positive angiogenic endothelial cells but also in most human ovarian cancer cells, in disseminated tumors treated with i.p. administered YB-1 ASO^A^ ([Figure 7](#fig7){ref-type="fig"}C).Figure 7Antitumor Efficacy of i.p. Administered YB-1 ASO^A^ in Mice Harboring Peritoneal Dissemination(A) qRT-PCR analysis shows an inhibition of mouse and human *YBX1* expression in peritoneally disseminated RMG-1 tumors treated with i.p. administered YB-1 ASO^A^. \*p \< 0.05; n = 3. Values are normalized to those for mouse and human 18S rRNAs. (B) Disseminated RMG-1 tumor growth was inhibited on day 21 in mice treated with YB-1 ASO^A^ (once per week for 3 weeks at 10 mg/kg body weight) compared with control ASOs. \*p \< 0.05; n = 5. Data are means ± SD. (C) Immunohistochemistry for CD31 and YB-1 or c-caspase-3 using laser confocal microscopy. The images show decreased YB-1 and increased c-caspase-3 levels in not only CD31-positive angiogenic endothelial cells but also most disseminated RMG-1 cancer cells after i.p. administration of YB-1 ASO^A^. Scale bar, 50 μm.

Discussion {#sec3}
==========

In this study, we have established a platform of AmNA-modified YB-1 targeted ASOs that inhibit multiple angiogenic signals (YB-1/Bcl-xL/VEGFR2 and YB-1/Bcl-xL/Tie signaling axes) and elicit apoptosis of tumor vessels in several xenograft models, suggesting a potential of YB-1 ASO^A^ as a novel tumor dormancy therapy.

To elucidate the role of YB-1 in angiogenesis in a tumor microenvironment, we screened the ASO sequences to inhibit YB-1 expression and then generated chemically modified YB-1 ASO^A^ and YB-1 ASO^L^ for in vivo use, which were confirmed for higher thermal stability ([Figure 1](#fig1){ref-type="fig"}B) and more efficient knockdown of YB-1 ([Figure 1](#fig1){ref-type="fig"}C) in cancer and vascular endothelial cells compared with YB-1 ASO^NA^. We next compared two modified YB-1 ASOs and found that YB-1 ASO^A^ had no toxicity, unlike YB-1 ASO^L^, which showed hepatotoxicity with elevated ALT and T. Bil in blood chemistry tests ([Figure 1](#fig1){ref-type="fig"}E). A study has shown RNase H1-dependent hepatotoxicity caused by gapmer-structured ASOs, such as LNA-modified ASOs.[@bib29] The toxicity of AmNA-ASOs has been little studied. Because the structural design of YB-1 ASO^A^ was identical to that of YB-1 ASO^L^ as a gapmer-type modification, the difference in hepatotoxicity might be explained by a higher RNase H1-independent toxicity of LNA-ASOs compared with AmNA-ASOs, whereas α-~L~-LNA-modified ASOs have been developed to reduce hepatotoxicity but represent a higher propensity for immune stimulation.[@bib30] Therefore, we employed YB-1 ASO^A^ to examine the role of YB-1 in tumor growth and angiogenesis in xenograft tumor mice models.

Because YB-1 is a negative regulator for apoptosis in cancer cells,[@bib22], [@bib31] we first hypothesized that YB-1 ASO^A^ acted directly on cancer cells, suppressed their YB-1 expression and induced apoptosis. However, when YB-1 ASO^A^ was administered i.v. to subcutaneous xenografts, the outcome was different from our hypothesis, with YB-1 suppression not in the human cancer cells but solely in the mouse cells ([Figure 2](#fig2){ref-type="fig"}D). This indicates that the antitumor efficacy observed in i.v. treated xenografts was probably not caused by direct effects on the cancer cells, even though YB-1 ASO^A^ was distributed to tumor tissues, as well as kidneys ([Figures 2](#fig2){ref-type="fig"}A and 2B). Our second hypothesis was that YB-1 ASO^A^ affected tumor growth by downregulating vascularization in the tumor tissues,[@bib32] because YB-1 is overexpressed in tumor vessels in a variety of solid tumors[@bib13] and the activity of phosphorothioate ASOs has been shown in the tumor microenvironment.[@bib33], [@bib34], [@bib35] The immunohistochemical analysis by double staining of CD31 and YB-1 in subcutaneous tumor tissues showed that i.v. administered YB-1 ASO^A^ suppressed YB-1 expression primarily in mouse vascular endothelial cells and induced their apoptosis, leading to angiogenesis inhibition. This may be caused by YB-1 ASO^A^ reagents being delivered to the tumor vessels efficiently rather than inside the tumor nests. Moreover, gene mutations rarely occur in the tumor vessels, indicating that YB-1 ASO^A^ resistance may not be frequently induced by YB-1 ASO^A^ treatment.

A novel pathway for YB-1 ASO^A^-mediated endothelial cell apoptosis may be through suppressing Bcl-2 and/or Bcl-xL, major antiapoptotic members of the Bcl-2 protein family, because Bcl-2 promotes angiogenesis in tumor microenvironments by enhancing VEGF expression and HIF-1 transcriptional activity[@bib25], [@bib36], [@bib37], [@bib38] and Bcl-xL upregulates angiogenesis through secretion of interleukin-8, an angiogenic factor, from cancer cells.[@bib39], [@bib40], [@bib41] Our microarray analysis showed the interaction of YB-1 with the Bcl-xL signal in vascular endothelial cells. It has been reported that osteopontin-induced angiogenesis is mediated by phosphatidylinositol 3-kinase (PI3K)/AKT, an inducer of YB-1 activation,[@bib42] and by ERK signals, concomitant with upregulation of Bcl-xL and nuclear factor κB (NF-κB),[@bib43] and that co-stimulation of VEGF and angiopoietin-1 promotes angiogenesis with upregulated Bcl-xL and downregulated caspase-3 in myocardial infarction heart.[@bib44] Thus, we examined the involvement of Bcl-xL in VEGF/VEGFR and angiopoietin/Tie signals in vascular endothelial cells. In HUVECs and HPAECs treated with YB-1 ASO^A^ and Bcl-xL siRNA, YB-1 knockdown-mediated Bcl-xL reduction inhibited the expression of VEGFR2 and Tie-1/-2 receptors, irrespective of caspase activation. These results indicate that the mechanism of antiangiogenic function of YB-1 ASO^A^ may be mediated by the blockade of VEGF/VEGFR2 and angiopoietin/Tie signaling pathways. The mechanism was examined in human vascular endothelial cell lines, because mouse cell lines of vascular endothelia are not established and our final goal is a clinical application. It was confirmed that YB-1 ASO^A^ incubation without transfection reagents inhibited YB-1 expression in mouse tumor cells in a dose-dependent manner ([Figure S8](#mmc1){ref-type="supplementary-material"}), although the YB-1 ASO^A^ activity plateaued around 500--750 nM. Inhibited VEGFR2/Tie signals and induction of apoptosis in mouse tumor vessels was likely induced by the YB-1 knockdown effect, because the sensitivity to YB-1 ASO^A^ was higher in vascular endothelial cells compared with tumor cells.

The two signal pathways of VEGF/VEGFR and angiopoietin/Tie independently regulate tumor angiogenesis,[@bib45], [@bib46] indicating that angiogenic inhibitors affecting both pathways would be highly effective compared with single-target reagents. Because VEGFR2 and Tie2 expression was inhibited by i.v. administered YB-1 ASO^A^ in angiogenic endothelial cells in a tumor microenvironment, it is not surprising that YB-1 ASO^A^, when given i.v., induced apoptosis to tumor vessels in a bevacizumab-resistant xenograft tumor model. The safety potential of YB-1 ASO^A^ was confirmed by body weight ([Figure S9](#mmc1){ref-type="supplementary-material"}) and blood examinations ([Table 1](#tbl1){ref-type="table"}). In addition, YB-1 ASO^A^, when given i.p, distributed to peritoneally disseminated tumors more efficiently compared with i.v. administration to subcutaneous tumors ([Figure S10](#mmc1){ref-type="supplementary-material"}), inhibited both mouse and human YB-1 expression, and exhibited higher antitumor efficacy against peritoneal dissemination via the mechanism of direct apoptosis to cancer cells ([Figure 7](#fig7){ref-type="fig"}). Therefore, YB-1 ASO^A^, unlike anti-VEGF antibodies or tyrosine kinase inhibitors of VEGFR,[@bib47] could act not only on tumor vessels but also on cancer cells, which may depend on the distribution routes and infiltration efficiency of ASO reagents into tumor nests. For future clinical applications, we are evaluating the maximum tolerated dose and therapeutic windows using three animal species (mouse, rat, and cynomolgus monkey).Table 1Blood Tests in Mice after i.v. Administration of YB-1 ASO^A^Suit2-GR Subcutaneous TumorWBC (10^2^/μL)RBC (10^4^/μL)HGB (g/dL)HCT (%)PLT (10^4^/μL)Saline43 ± 5752 ± 2211.9 ± 0.537.3 ± 1.494.2 ± 27.0Ctrl ASO29 ± 12779 ± 3912.2 ± 0.638.5 ± 2.1100.5 ± 33.3YB-1 ASO^A^54 ± 14741 ± 4811.8 ± 0.937.4 ± 2.490.4 ± 26.9**BUN (mg/dL)Cre (mg/dL)AST (IU/L)ALT (IU/L)T. Bil (mg/dL)**Saline32.4 ± 3.70.10 ± 0.01147 ± 10337 ± 150.02 ± 0.01Ctrl ASO27.9 ± 5.40.10 ± 0.03170 ± 18345 ± 190.03 ± 0.01YB-1 ASO^A^24.6 ± 3.50.09 ± 0.01158 ± 7158 ± 290.03 ± 0.02**HCT116 Subcutaneous TumorWBC (10**^**2**^**/μL)RBC (10**^**4**^**/μL)HGB (g/dL)HCT (%)PLT (10**^**4**^**/μL)**Ctrl ASO48 ± 8715 ± 5513.1 ± 0.335.7 ± 2.7136.2 ± 10.8YB-1 ASO^A^39 ± 9696 ± 4313.0 ± 0.635.5 ± 2.3123.7 ± 40.5**BUN (mg/dL)Cre (mg/dL)AST (IU/L)ALT (IU/L)T. Bil (mg/dL)**Ctrl ASO21.2 ± 2.00.07 ± 0.0380 ± 1026 ± 30.06 ± 0.02YB-1 ASO^A^17.4 ± 2.60.08 ± 0.04148 ± 3977 ± 190.06 ± 0.02[^1]

In conclusion, YB-1/Bcl-xL/VEGFR2 and YB-1/Bcl-xL/Tie signaling axes play important roles in angiogenesis and YB-1 ASO^A^ could exert antitumor efficacy against a variety of cancers by inducing apoptotic changes in new blood vessels. YB-1 ASO^A^ may, therefore, exemplify a novel strategy of tumor dormancy therapy.

Materials and Methods {#sec4}
=====================

ASOs {#sec4.1}
----

Phosphorothioate ASOs containing DNA, LNA, or AmNA monomers ([Figure 1](#fig1){ref-type="fig"}A; [Figure S1](#mmc1){ref-type="supplementary-material"}) were synthesized using an automated DNA synthesizer by GeneDesign (Ibaraki, Japan), based on methods described by Nishina et al.[@bib48] The 3′ end of LNA-ASOs or AmNA-ASOs was not chemically modified because of very low efficiency of AmNA-ASO synthesis. To select YB-1 ASOs with high knockdown efficiency, we performed screening experiments using real-time PCR (qRT-PCR) in several cancer cell lines transfected with LNA-type ASOs targeting 64 sites on the YB-1 mRNA. In the selected LNA-ASOs, we replaced LNA monomers at the flanked regions of the ASOs with AmNA monomers ([Figure 1](#fig1){ref-type="fig"}A) to compare in vitro knockdown efficiency and in vivo safety potentials between LNA-ASOs and AmNA-ASOs. Finally, we changed the length of ASOs from 13 to 18 nucleotides to optimize the length of YB-1 ASOs with the highest knockdown efficiency. Evaluation of ASO properties was described in [Supplemental Materials and Methods](#mmc1){ref-type="supplementary-material"}.

Cell Culture {#sec4.2}
------------

The primary human endothelial cells, HUVECs (C2519A) and HPAECs (CC-2530), were from Lonza (Tokyo, Japan). Human pancreatic MIA PaCa-2 and colorectal HCT116 carcinoma cell lines were from the American Type Culture Collection (ATCC, Manassas, VA, USA), and the ovarian cancer RMG-1 cell line was from Japanese Health Science Research Resources Bank (Osaka, Japan). The gemcitabine-resistant human pancreatic Suit2-GR cancer cell line was a gift from Dr. Masao Tanaka (Kyushu University).[@bib49] Suit2-GR and HCT116 cell lines stably expressing luciferase were established as previously reported.[@bib50] HUVECs and HPAECs were cultured in EGM-2 basal media (Lonza) supplemented with the SingleQuots Kit (Lonza). HCT116 and RMG-1 cells were cultured in RPMI 1640 (Nacalai Tesque, Tokyo, Japan), and MIA PaCa-2 and Suit2-GR cells were cultured in DMEM (Nacalai Tesque), all supplemented with 10% heat-inactivated fetal bovine serum (FBS) (Gibco, Tokyo, Japan), penicillin (100 U/mL), and streptomycin (100 μg/mL). Cells were cultured at 37°C in a humidified atmosphere equilibrated with 95% air and 5% CO~2~.

Antibodies and Reagents {#sec4.3}
-----------------------

We obtained antibodies against cleaved caspase-3 (Cell Signal, Tokyo, Japan), CD31 (BD Pharmingen, Tokyo, Japan), cytochrome *c* (BD Pharmingen), Tom20 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), VEGFR1 (Abcam, Tokyo, Japan), VEGFR2 (Cell Signal), Bcl-xL (Cell Signal), Tie1 (Santa Cruz), Tie2 (Santa Cruz), and β-actin (Sigma-Aldrich, St. Louis, MO, USA). A polyclonal antibody against recombinant YB-1 was provided by Dr. Michihiko Kuwano (Kyushu University). The VECTASTAIN Elite HRP ABC Kit (rabbit immunoglobulin G \[IgG\] and rat IgG) and Peroxidase Substrate Kit were obtained from Vector Laboratories (Burlingame, CA, USA).

In Vitro Transfection of ASOs and siRNAs {#sec4.4}
----------------------------------------

Cells were plated at 3 × 10^3^--1 × 10^4^ cells/cm^2^ 24 hr before transfection. Cells were transfected with siRNA duplexes or ASOs at the indicated concentration using RNAiMAX (Invitrogen), according to the manufacturer's protocol.

Real-Time RT-PCR Analysis {#sec4.5}
-------------------------

Total RNA was extracted using a High Pure RNA Isolation Kit (Roche, Tokyo, Japan). Real-time RT-PCR was performed with a QuantiTect SYBR Green Reverse Transcription-PCR Kit (Roche) on a Light Cycler 480 II instrument (Roche). The data from qRT-PCR were normalized to the data for a housekeeping gene, either 18S rRNA or human B2M. PCR amplification was performed in three independent experiments. The probe to detect YB-1 was Universal ProbeLibrary Probe \#16 (Roche). Sets of primers were 5′-cgc agt gta gga gat gga gag-3′ and 5′-gaa cac cac cag gac ctg taa-3′ for YB-1; 5′-gta acc ccg ttg aac ccc att-3′ and 5′-cca tcc aat cgg tag tag cg-3′ for 18S; and ProbeLibrary sets for human B2M gene (Roche).

Microarray Analysis {#sec4.6}
-------------------

Total RNA was extracted from control or YB-1 ASO^A^-transfected HUVECs and HPAECs. The quality of RNA in each sample was evaluated using Expression RNA Analysis kits and an automated electrophoresis system (Bio-Rad, Hercules, CA, USA), according to the manufacturer's protocol. Biotinylated cDNA was prepared from 0.5 μg total RNA using an Ambion WT Expression Kit (Thermo Fisher Scientific, Yokohama, Japan) and hybridized with Human Gene 2.1 ST Array strips at 45°C for 16 hr. Array slides were washed, stained, and scanned in the GeneAtlas System (Affymetrix, Santa Clara, CA, USA). Microarray data analysis was performed using GeneSpring GX 13.1 software (Agilent Technologies, Santa Clara, CA).

Western Blot Analysis {#sec4.7}
---------------------

Cultured cells were harvested into SDS buffer (60 mM Tris-HCl \[pH 6.8\], 0.5% glycerol, 2% SDS). Protein concentrations were quantified using the BCA assay (Thermo Fisher Scientific, Waltham, MA, USA). Extract samples (15 μg protein) were electrophoresed on precast acrylamide gels (Invitrogen). The protein bands were transferred to polyvinylidene fluoride (PVDF) membranes (New England Biolabs, Tokyo, Japan). The membranes were incubated with the primary antibody at 4°C overnight, followed by incubation with horseradish peroxidase (HRP)-labeled secondary antibody at room temperature for 1 hr. Chemiluminescent detection was performed with the ECL Prime reagent (GE Healthcare, Tokyo, Japan).

Immunohistochemical Analysis {#sec4.8}
----------------------------

Fresh tissues were embedded in OCT freezing medium and frozen using Histo-Tek PINO (AS ONE, Osaka, Japan). Tissues were sectioned at an 8 μm thickness, fixed with 4% paraformaldehyde solution (Wako, Osaka, Japan) for 15 min at room temperature, and pretreated with methanol containing 1% hydrogen peroxide for 30 min at room temperature to quench endogenous peroxidase. The sections were incubated with a primary antibody at 4°C overnight and the secondary antibody for 30 min at room temperature, followed by histochemical detection using the ABC system (Vector Laboratories) with hematoxylin counterstaining. Images were acquired with an Eclipse 55i upright microscope (Nikon, Tokyo, Japan). Immunofluorescence images were acquired with a C2 confocal microscope (Nikon) after incubation with Alexa Fluor-conjugated secondary antibodies (Invitrogen). For analysis of cytochrome *c* release, HUVECs and HPAECs were grown on coverslips (Matsunami, Osaka, Japan). Cells were transfected with YB-1 ASO^A^ in the presence of 100 μM z-VAD-FMK, a broad caspase inhibitor. Cells were fixed and immunostained for cytochrome *c* as described earlier.

Cell Proliferation Assay {#sec4.9}
------------------------

Cell proliferation was quantified with Cell Counting Kit-8 (Dojindo, Kumamoto, Japan), according to the manufacturer's protocol, on days 0, 1, and 2 after transfection. The absorbance at 450 nm was measured using a GloMax-Multi+ Microplate Multimode Reader (Promega, Tokyo, Japan).

Cell-Cycle Analysis {#sec4.10}
-------------------

Cells were harvested with trypsin, washed with PBS, and fixed in ice-cold 70% ethanol for 1 hr. After resuspension in PBS containing 0.1% BSA, cells were treated with RNase (50 μg/mL; Thermo Fisher Scientific) for 15 min, stained with propidium iodide (50 μg/mL; Nacalai Tesque) for 15 min, and subjected to cell-cycle analysis using a flow cytometer (FACS Canto II; BD Biosciences).

Tube Formation Assay with Human Microvascular Endothelial Cells {#sec4.11}
---------------------------------------------------------------

Growth factor-depleted Matrigel (Corning, Tokyo, Japan) was added to plates at 150 μL/cm^2^ and incubated at 37°C for 30 min to allow the gel to solidify. Human microvascular endothelial cells (HUVECs or HPAECs, 3.5 × 10^4^ cells/cm^2^) were then plated onto the Matrigel. After 5.5 hr incubation at 37°C in 95% air and 5% CO~2~, bright-field images were acquired with Digital Sight DS-Qi1Mc (Nikon). Ten images per sample were obtained, and the total length of tube-like structures in each field was measured using ImageJ software (NIH, Bethesda, MD, USA).

Animals and Study Approval {#sec4.12}
--------------------------

All animal experiments were conducted in accordance with a protocol approved by the Animal Care and Use Committee at Kyushu University. Female 6-week-old athymic nude mice (BALB/cAnNCrj-nu) were purchased from Charles River Laboratories Japan (Yokohama, Japan) and allowed to acclimatize for 1 week before the start of experiments.

In Vivo Treatments {#sec4.13}
------------------

Subcutaneous tumor models were prepared by injecting nude mice with pancreatic Suit2-GR or colorectal HCT116 cancer cells (1 × 10^6^ cells/mouse) in the flanks. After 1 week, YB-1 ASO^A^ solutions were administered via tail vein once per week for 3 weeks at a dose of 10 mg/kg (days 0, 7, and 14). Tumor size was calculated using the formula ***a*** × 1/2 × ***b***^2^ (***a***, long; ***b***, short tumor distance) each week. On day 21, tumor, liver, and kidney tissues were obtained to determine knockdown efficiency and antiangiogenic effects of the treatments by immunohistochemistry for CD31 and cleaved caspase-3. Blood samples were collected and subjected to hematology and blood chemistry tests to assess the safety of i.v. administered YB-1 ASO. In a separate experiment, YB-1 ASO^A^ (10 mg/kg) was administered i.v. once per week for 4 weeks in mice with subcutaneous Suit2-GR tumors, and this treatment was compared with bevacizumab antibody (10 mg/kg), given twice per week for the same period. Efficacy was determined by assessing tumor growth and microvascular density in tumor tissues on day 28.

Peritoneal dissemination was generated by i.p. implantation of RMG-1 ovarian cancer cells in nude mice (5 × 10^5^ cells/mouse). After 1 week, YB-1 ASO^A^ (10 mg/kg) was administered i.p. once per week for 3 weeks (days 0, 7, and 14). Antitumor efficacy was evaluated by tumor weight on day 21.

Statistical Analysis {#sec4.14}
--------------------

Statistical analyses were performed using JMP Pro 12 software (SAS Institute, Cary, NC, USA). All data are represented as means ± SD. Student's t test was used to compare mean values between two groups. Values of p \< 0.05 were considered statistically significant.
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[^1]: YB-1 ASO^A^ or control (Ctrl) ASOs (10 mg/kg body weight \[BW\]) were i.v. administered to nude mice harboring Suit2-GR or HCT116 subcutaneous tumors once per week for 3 weeks. Blood samples were collected 1 week after the final administration of ASOs and subjected to the blood examinations. WBC, white blood cell; RBC, red blood cell; HGB, hemoglobin; PLT, platelet.
